Zenas BioPharma Archives | Page 2 of 2 | Be Korea-savvy
Zenas BioPharma Secures $118 Million to Advance Its Broad Pipeline of Autoimmune Disease Therapeutics

Zenas BioPharma Secures $118 Million to Advance Its Broad Pipeline of Autoimmune Disease Therapeutics

WALTHAM, Mass., Nov. 9 (Korea Bizwire) — Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies, today announced proceeds of $118 million in connection with the issuance of Series B preferred shares. In addition to Enavate Sciences, which led the Series B equity financing, new [...]

Zenas BioPharma Appoints Simon Lowry, M.D. as Chief Medical Officer

Zenas BioPharma Appoints Simon Lowry, M.D. as Chief Medical Officer

WALTHAM, Mass. and SHANGHAI, China, Sept. 7 (Korea Bizwire) — Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies for patients in need around the world, today announced the appointment of Simon Lowry, M.D., as the company’s Chief Medical Officer. Dr. Lowry brings over 20 [...]

Zenas BioPharma Obtains IND Approval in China for Phase 1/2 Study of ZB001 for the Treatment of Thyroid Eye Disease

Zenas BioPharma Obtains IND Approval in China for Phase 1/2 Study of ZB001 for the Treatment of Thyroid Eye Disease

WALTHAM, Mass and SHANGHAI, China, July 31 (Korea Bizwire) — Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies for patients in need around the world, announced that it has received approval of its Investigational New Drug (IND) application from the National Medical Products Administration [...]

Zenas BioPharma Submits Investigational New Drug Application in China for ZB001 for the Treatment of Thyroid Eye Disease

Zenas BioPharma Submits Investigational New Drug Application in China for ZB001 for the Treatment of Thyroid Eye Disease

WALTHAM, Mass. and SHANGHAI, China, May 15 (Korea Bizwire) — Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies for patients in need around the world, today announced the submission of an investigational new drug (IND) application to the China National Medical Products Administration (NMPA) [...]

Zenas BioPharma Appoints Dr. John Orloff to Board of Directors

Zenas BioPharma Appoints Dr. John Orloff to Board of Directors

BOSTON and SHANGHAI, China, Jan. 6 (Korea Bizwire) — Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and delivery of immune-based therapies, today announced the appointment of John Orloff, MD to its Board of Directors. Dr. Orloff joins the Zenas Board with over 25 years of experience successfully leading [...]

Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor

Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor

MONROVIA, Calif., HONG KONG and BOSTON, Nov. 21 (Korea Bizwire) — Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, and Zenas BioPharma (“Zenas”), a global biopharmaceutical company based in the USA and China committed to the development and delivery of immune-based [...]

Zenas BioPharma Announces New Executive Leadership Appointments

Zenas BioPharma Announces New Executive Leadership Appointments

HONG KONG and BOSTON, May 3 (Korea Bizwire) — Zenas BioPharma (“Zenas”), a cross-border (China-USA based) biopharmaceutical company committed to the development and delivery of immune-based therapies, today announced the appointment of Hua Mu, MD, Ph.D. as President and Chief Executive Officer and Acting Chief Medical Officer and Joe Farmer as Chief Business and Administrative [...]

Zenas BioPharma Launches as a Cross-Border Biopharmaceutical Company to Bring Innovation to the Development and Delivery of Immune-Based Therapies

Zenas BioPharma Launches as a Cross-Border Biopharmaceutical Company to Bring Innovation to the Development and Delivery of Immune-Based Therapies

HONG KONG and BOSTON, March 23 (Korea Bizwire) — Zenas BioPharma (“Zenas”) launched today as a cross-border biopharmaceutical company committed to becoming a global leader in the development and delivery of immune-based therapies for patients in China and throughout the world. Zenas was founded and initially funded by Tellus BioVentures, LLC (“Tellus”) and Fairmount Funds [...]